Rani Therapeutics Holdings, Inc. (RANI)Healthcare | Biotechnology | San Jose, United States | NasdaqGM
0.63 USD
-0.05
(-7.945%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.63 +0.00 (0.079%) ⇧ (July 13, 2026, 7:31 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:48 a.m. EDT
The investment case for Rani Therapeutics is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. The stock has lost 94.75% of its value over the last three years, with every single year showing a negative return, signaling a deep structural failure in the market's valuation of the business. While the company boasts a pristine balance sheet with minimal debt and a current ratio of 3.4, these strengths are irrelevant in a biotech sector where capital preservation is paramount without a proven product pipeline. The recent partnership with PegBio offers a glimmer of hope for the obesity drug pipeline, but it is insufficient to reverse the trend of eroding shareholder value. Options activity confirms this pessimism, with traders aggressively buying protection at lower strikes while avoiding long calls. With no dividend to provide income and a history of massive annual declines, this is a security to avoid until there is concrete evidence of sustained revenue growth and a stabilization in the share price. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111765 |
| AutoARIMA | 0.116989 |
| AutoETS | 0.117522 |
| MSTL | 0.117848 |
| MSTL_95 | 0.132305 |
| MSTL_78_95 | 0.149086 |
| MSTL_78 | 0.204735 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.337 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.088 |
| Revenue per Share | 0.031 |
| Market Cap | 86,972,200 |
| Forward P/E | -2.92 |
| Beta | 0.80 |
| Website | https://www.ranitherapeutics.com |
As of July 11, 2026, 5:48 a.m. EDT: Speculators are positioning for a continued decline, evidenced by heavy put volume relative to calls across nearly all expirations. Open interest is concentrated significantly out-of-the-money on the downside (strikes at $0.50 and $2.00), while call activity is sparse and mostly clustered near the money or slightly out-of-the-money. This distribution suggests a 'bearish gamma' environment where traders are betting on further downside rather than a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.01575929 |
| Address1 | 2,051 Ringwood Avenue |
| All Time High | 36.27 |
| All Time Low | 0.387 |
| Ask | 0.8041 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 712,880 |
| Average Daily Volume3 Month | 872,834 |
| Average Volume | 872,834 |
| Average Volume10Days | 712,880 |
| Beta | 0.795 |
| Bid | 0.476 |
| Bid Size | 2 |
| Book Value | 0.285 |
| City | San Jose |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6326 |
| Current Ratio | 3.399 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.6904 |
| Day Low | 0.6126 |
| Debt To Equity | 11.088 |
| Display Name | Rani Therapeutics |
| Earnings Call Timestamp End | 1,774,557,000 |
| Earnings Call Timestamp Start | 1,774,557,000 |
| Earnings Timestamp | 1,778,875,200 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -33,826,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.913 |
| Enterprise To Revenue | 9.745 |
| Enterprise Value | 30,880,656 |
| Eps Current Year | -0.18667 |
| Eps Forward | -0.21667 |
| Eps Trailing Twelve Months | -0.25 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.87022 |
| Fifty Day Average Change | -0.23762 |
| Fifty Day Average Change Percent | -0.27305737 |
| Fifty Two Week Change Percent | -1.5759289 |
| Fifty Two Week High | 3.87 |
| Fifty Two Week High Change | -3.2373998 |
| Fifty Two Week High Change Percent | -0.8365374 |
| Fifty Two Week Low | 0.387 |
| Fifty Two Week Low Change | 0.24560001 |
| Fifty Two Week Low Change Percent | 0.6346254 |
| Fifty Two Week Range | 0.387 - 3.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 69,146,454 |
| Forward Eps | -0.21667 |
| Forward P E | -2.9196475 |
| Free Cashflow | -5,224,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 3,169,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.049879998 |
| Held Percent Institutions | 0.43883 |
| Implied Shares Outstanding | 137,483,705 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. |
| Long Name | Rani Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 86,972,200 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_242425883 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -29,442,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 77,233,825 |
| Number Of Analyst Opinions | 4 |
| Open | 0.6904 |
| Operating Cashflow | -17,062,000 |
| Operating Margins | -4.88232 |
| Payout Ratio | 0.0 |
| Phone | 408 457 3700 |
| Post Market Change | 0.00049996376 |
| Post Market Change Percent | 0.07903316 |
| Post Market Price | 0.6331 |
| Post Market Time | 1,783,985,505 |
| Previous Close | 0.6872 |
| Price Eps Current Year | -3.388868 |
| Price Hint | 4 |
| Price To Book | 2.219649 |
| Price To Sales Trailing12 Months | 27.444683 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.285 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0546 |
| Regular Market Change Percent | -7.94528 |
| Regular Market Day High | 0.6904 |
| Regular Market Day Low | 0.6126 |
| Regular Market Day Range | 0.6126 - 0.6904 |
| Regular Market Open | 0.6904 |
| Regular Market Previous Close | 0.6872 |
| Regular Market Price | 0.6326 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,103,704 |
| Return On Assets | -0.56964 |
| Return On Equity | -2.39962 |
| Revenue Growth | 8.93 |
| Revenue Per Share | 0.031 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 112,389,152 |
| Shares Percent Shares Out | 0.0808 |
| Shares Short | 9,080,206 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,383,189 |
| Short Name | Rani Therapeutics Holdings, Inc |
| Short Percent Of Float | 0.083000004 |
| Short Ratio | 12.08 |
| Source Interval | 15 |
| State | CA |
| Symbol | RANI |
| Target High Price | 11.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.5 |
| Target Median Price | 7.0 |
| Total Cash | 43,403,000 |
| Total Cash Per Share | 0.434 |
| Total Debt | 3,941,000 |
| Total Revenue | 3,169,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.187435 |
| Two Hundred Day Average Change | -0.554835 |
| Two Hundred Day Average Change Percent | -0.46725506 |
| Type Disp | Equity |
| Volume | 1,103,704 |
| Website | https://www.ranitherapeutics.com |
| Zip | 95,131 |